Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 14/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.58 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27090233 | 0.98 | ESR1 (0.96) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL4032655 | 0.90 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL18726303 | 0.90 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL5901662 | 0.89 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL16901786 | 0.89 | ESR1 (0.79) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL4077794 | 0.88 | ESR1 (1.00) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL13254489 | 0.87 | ESR2 (0.77) | ESR1ESR2PIK3CAPIK3CBNPC1 | |
| SCHEMBL10061932 | 0.86 | SMN1; SMN2 (0.81) | ESR1ESR2PIK3CAPIK3CBNPC1 | |
| SCHEMBL2244982 | 0.86 | RAB9A (0.81) | ESR1ESR2PIK3CAPIK3CBNPC1 | |
| SCHEMBL10565801 | 0.86 | ESR1 (0.76) | ESR1ESR2PIK3CAPIK3CBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GEORG AUGUST UNIV GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVS (DE) | 2024-01-04 | — | — | US | claimed |
| EP-4729471-A2 | NOVEL LIGAND ASSAYS | InsituGen Limited (NZ) | 2026-04-22 | — | — | EP | disclosed |
| EP-3966573-B1 | NOVEL LIGAND ASSAYS | INSITUGEN LTD (NZ) | 2026-04-22 | — | — | EP | disclosed |
| EP-4638700-A2 | RECOMBINANT FUNGAL STRAINS AND METHODS THEREOF FOR PRODUCING CONSISTENT PROTEINS | Danisco US Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320512-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN FUNGAL CELLS | DANISCO US INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4563596-A1 | ANTI-CD163 ANTIBODIES WITH IMPROVED ADCC CAPABILITIES | OncoSpear ApS (DK) | 2025-06-04 | — | — | EP | disclosed |
| CN-119932057-A | Bisphenol F degradation gene cluster bpf and application thereof | 南京农业大学三亚研究院 | 2025-05-06 | — | — | CN | disclosed |
| US-12195732-B2 | Direct cloning | GENE BRIDGES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| EP-4441202-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN FUNGAL CELLS | Danisco US Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118574921-A | Compositions and methods for enhancing protein production in fungal cells | 丹尼斯科美国公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| CN-1646504-A | Substituted benzoxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885PIK3CA 2460/4885 |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885PIK3CA 2460/4885 |
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | ESR1 6/4885ESR2 3/4885PIK3CA 2788/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885PIK3CA 2451/4885 |
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GAA, GBA1, STS | ESR1 4234/4885ESR2 3235/4885PIK3CA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.